TABLE 2.
Functional characterization of HBV reactivation
| Reference | Study Population | Treatment | Sequencing Approach | HBV Genotypes (N) |
|---|---|---|---|---|
| HBV Genomic Region(s) | Country | |||
| 68 | Stem cell transplant recipients | Lamivudine or none | Population sequencing | Genotype D (3) |
| Genotype F (1) | ||||
| P/S | Italy | |||
| 69 | HBsAg spontaneous clearers | None | Clonal sequencing | Genotype C (2) |
| Genotypes C + I (1) | ||||
| S | China | |||
| 27 | Occult HBV + HIV | Lamivudine-containing ART | Population sequencing | Genotype D (1) |
| P/S | Italy | |||
| 70 | Occult HBV | Chemotherapy | Clonal sequencing | Genotype not reported (3) |
| PreS/S | Italy | |||
| 71 | Occult HBV | ART | Clonal sequencing | Genotype A (1) |
| Genotype E (1) | ||||
| Full genome | Germany & Zaire | |||
| 72 | Occult HBV + HIV | Interruption of ART | Population sequencing | Genotype A (1) |
| P, S, PreC | Italy | |||
| 73 | Chronic + occult HBV | Chemotherapy | Clonal sequencing | Genotype not reported (1) |
| PreC/Core | Greece | |||
| 74 | Occult HBV | Chemotherapy | Population & clonal sequencing | Genotype C (2) |
| Genotype D (5) | ||||
| P/S | France | |||
| 75 | Occult HBV | Chemotherapy | Population sequencing | Genotype A (1) |
| Genotype B (2) | ||||
| Genotype C (8) | ||||
| P/S | Japan | |||
| 76 | Occult HBV | Chemotherapy | Population sequencing | Genotype A (1) |
| Genotype C (2) | ||||
| Genotype D (13) | ||||
| P/S | France | |||
| 77 | Occult HBV | Chemotherapy | Population sequencing | Genotype D (5) |
| Full genome | Egypt | |||
| 78 | Occult HBV | Termination of immunosuppressive therapy | Deep sequencing | Genotype B (5) |
| Genotype C (9) | ||||
| Full genome | Japan | |||
| 79 | Occult HBV | Chemotherapy | Clonal sequencing | Genotype C (1) |
| Full genome | Japan | |||
Abbreviations: ART, antiretroviral therapy; HBsAg, hepatitis B surface antigen; P, polymerase gene; PreC, PreCore region; PreSurface region; S, surface gene.